Indication
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Loading your page…
Loading your page…
Dementia;Alzheimer Disease;Parkinson Disease
Marketing Authorisation Holder: Novartis Europharm Limited
EMA Authorisation: 11/05/1998
INN: rivastigmine
AI Drug & Interaction Analysis
Free account required
Ask Osler about Exelon: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.